Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX-NK/HCC with HAIC in Locally Advanced HCC
NCT05040438Phase 2Completed
- Sponsor
- Vaxcell-Bio Therapeutics Co., Ltd.
- Start
- Oct 2019
- Primary completion
- Sep 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Vax-NK/HCC in hepatocellular carcinoma (HCC), sponsored by Vaxcell-Bio Therapeutics Co., Ltd.. Started Oct 2019; status: completed.
02
Drugs
Vax-NK/HCC
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05040438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040438.